Showing 2121-2130 of 2898 results for "".
- Nutrafol Launches Pro-Strength Boostershttps://modernaesthetics.com/news/nutrafol-launches-pro-strength-boosters/2473071/New professional-strength boosters from Nutrafol extend the popular nutraceutical line, providing physicians the opportunity to individualize recommendations for each patient’s specific hair health needs. Hairbiotic MD is a professional-strength
- It's A Deal: Eirion Therapeutics, Shanghai Haohai Biological Technology Close $40M Series A Investment and Licensing Dealhttps://modernaesthetics.com/news/its-a-deal-eirion-therapeutics-inc-shanghai-haohai-biological-technology-closes-40m-series-a-investment-and-licensing-deal/2473070/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- Solta Rolls Out Next Generation Clear + Brilliant Laserhttps://modernaesthetics.com/news/solta-rolls-out-next-generation-clear-brilliant-laser/2473069/Solta Medical is launching Clear + Brilliant Touch laser, the company’s next generation Clear + Brilliant laser. By seamlessly switching between two wavelengths with the Original and Perméa handpieces, physicians can now more easily deliver a
- PCA Skin Gears Up for National Peel Dayhttps://modernaesthetics.com/news/pca-skin-gears-up-for-national-peel-day/2473068/Next week brings the second annual National Peel Day. To coincide with the official holiday recognized by the National Day Archives on the National Day Registry on March 10, PCA Skin will unveil new branding this month. Among various social media ac
- Pre-clinical Data Suggest Soliton's RAP Technology Can Help Liver Fibrosishttps://modernaesthetics.com/news/pre-clinical-data-suggest-solitons-rap-technology-can-help-liver-fibrosis/2473066/A pre-clinical study in animals demonstrates positive results for Soliton’s RAP device as a potential treatment for liver fibrosis. Validated laboratory and histological assessments in a mouse model demonstrated that Rapid Acoustic Pulse (RAP) therapy reduced the effects of induced liver fi
- It’s Settled: AbbVie and Evolus Come to Agreementhttps://modernaesthetics.com/news/its-settled-abbvie-and-evolus-come-to-agreement/2473064/AbbVie, Evolus, and Medytox have agreed to new settlement agreements to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus
- Industry Responds to COVID-19: Biopelle, Galderma US Aestheticshttps://modernaesthetics.com/news/industry-responds-to-covid-19-biopelle-galderma-us-aesthetics/2473063/Biopelle One bright spot for many aesthetic practices during the COVID-19 pandemic has been persistent and perhaps increased demand for skincare. Biopelle has responded to support physicians who wish to dispense their products. “We offer a ski
- Soliton Receives Best New Technology Awardhttps://modernaesthetics.com/news/soliton-named-best-new-technology/2473062/Soliton's Rapid Acoustic Pulse (RAP) device received the Best New Technology Award from the Aesthetic Industry Association (AIA). The Soliton RAP device, which uses proprietary design acoustic shockwaves to mechanically disrupt targeted cellular structures in a completely
- ASDS Issues New Recommendations on Preventing and Treating Filler Complicationshttps://modernaesthetics.com/news/asds-issues-new-recommendations-on-preventing-and-treating-filler-complications/2473060/The American Society for Dermatologic Surgery (ASDS) Multispecialty Soft-tissue Fillers Guideline Task Force has
- FDA Greenlights Galderma's Restylane Defyne for Chin Augmentationhttps://modernaesthetics.com/news/fda-greenlights-galdermas-restylane-defyne-for-chin-augmentation/2473055/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201